Twist Bioscience Corporation $TWST Shares Newly Bought by Veracity Capital LLC

Veracity Capital LLC bought a new position in shares of Twist Bioscience Corporation (NASDAQ:TWST) in the 3rd quarter, Holdings Channel.com reports. The firm bought 3,755 shares of the company’s stock, valued at approximately $726,000.

Other large investors also recently added to or reduced their stakes in the company. GAMMA Investing LLC grew its holdings in Twist Bioscience by 24.4% in the second quarter. GAMMA Investing LLC now owns 943 shares of the company’s stock worth $97,000 after purchasing an additional 185 shares during the last quarter. Allworth Financial LP lifted its holdings in shares of Twist Bioscience by 54.9% during the 2nd quarter. Allworth Financial LP now owns 601 shares of the company’s stock valued at $62,000 after purchasing an additional 213 shares during the last quarter. PNC Financial Services Group Inc. boosted its position in shares of Twist Bioscience by 89.7% in the 1st quarter. PNC Financial Services Group Inc. now owns 958 shares of the company’s stock worth $46,000 after purchasing an additional 453 shares in the last quarter. Trifecta Capital Advisors LLC acquired a new stake in shares of Twist Bioscience in the 2nd quarter worth $63,000. Finally, Western Wealth Management LLC purchased a new position in Twist Bioscience during the 1st quarter worth $31,000.

Insider Activity

In related news, CFO Adam Laponis sold 8,057 shares of the firm’s stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $188.88, for a total transaction of $1,521,806.16. Following the sale, the chief financial officer owned 100,576 shares in the company, valued at approximately $18,996,794.88. This trade represents a 7.42% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Paula Green sold 10,088 shares of Twist Bioscience stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $188.88, for a total transaction of $1,905,421.44. Following the completion of the transaction, the senior vice president directly owned 106,632 shares of the company’s stock, valued at $20,140,652.16. The trade was a 8.64% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 599,458 shares of company stock valued at $93,383,392 in the last quarter. Company insiders own 3.08% of the company’s stock.

Twist Bioscience Stock Performance

Shares of TWST stock traded down $6.79 on Thursday, hitting $148.85. The company had a trading volume of 2,296,151 shares, compared to its average volume of 1,684,040. Twist Bioscience Corporation has a twelve month low of $23.30 and a twelve month high of $219.71. The company has a quick ratio of 2.38, a current ratio of 2.67 and a debt-to-equity ratio of 0.03. The firm has a market cap of $9.33 billion, a P/E ratio of -67.25 and a beta of 2.19. The company has a 50-day moving average price of $141.74 and a 200-day moving average price of $95.17.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings results on Monday, August 3rd. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.05). Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. The company had revenue of $118.38 million for the quarter, compared to analysts’ expectations of $114.55 million. During the same quarter in the prior year, the business posted $0.33 earnings per share. The firm’s revenue was up 23.2% compared to the same quarter last year. As a group, equities research analysts predict that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on TWST. TD Cowen reissued a “buy” rating on shares of Twist Bioscience in a report on Monday, August 3rd. Jefferies Financial Group started coverage on Twist Bioscience in a research note on Thursday. They issued a “hold” rating and a $150.00 target price for the company. Canaccord Genuity Group boosted their price target on Twist Bioscience from $90.00 to $120.00 and gave the company a “buy” rating in a research note on Tuesday, July 14th. Leerink Partners increased their price objective on Twist Bioscience from $160.00 to $190.00 and gave the company an “outperform” rating in a report on Tuesday, September 29th. Finally, UBS Group began coverage on Twist Bioscience in a report on Wednesday, September 9th. They set a “neutral” rating and a $144.00 target price for the company. Eight research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $128.17.

Twist Bioscience Company Profile

Twist Bioscience Corporation (NASDAQ:TWST) is a biotechnology company that develops and manufactures synthetic DNA using a silicon-based production platform. Its technology is designed to enable the precise, high-throughput synthesis of DNA at smaller scale and with potentially lower material consumption than traditional methods.

The company provides synthetic DNA products and services for applications in drug discovery and development, biotechnology research, agriculture, industrial chemicals and other life sciences markets.